--- title: "Why Is GeoVax Labs Stock Falling Tuesday?" type: "News" locale: "en" url: "https://longbridge.com/en/news/286923401.md" description: "GeoVax Labs (NASDAQ:GOVX) stock is down 13.57% in premarket trading after an 80% rally, following the announcement of a $3M private placement, raising concerns over shareholder dilution. The offering includes approximately 2.03 million shares and warrants for an additional 4.05 million shares. Despite the drop, the stock remains above its 20-day and 50-day SMAs, but is significantly below its 100-day and 200-day SMAs, indicating a long-term downtrend." datetime: "2026-05-19T13:29:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/286923401.md) - [en](https://longbridge.com/en/news/286923401.md) - [zh-HK](https://longbridge.com/zh-HK/news/286923401.md) --- # Why Is GeoVax Labs Stock Falling Tuesday? **GeoVax Labs, Inc.** (NASDAQ:GOVX) stock is pulling back in premarket trading on Tuesday after surging 79.67% to close sharply higher on Monday. The stock is falling after the company announced a $3 million private placement of stock and warrants, fueling investor concerns about shareholder dilution. The sell-off also reflects profit-taking following the stock's massive 80% rally in the previous session. ## Private Placement Details GeoVax Labs said Monday it priced a $3 million private placement financing with existing institutional investors. The deal includes about 2.03 million shares, or equivalents, along with Series A and Series B warrants tied to an additional 4.05 million shares, all with an exercise price of $1.48 per share. The clinical-stage biotech company said it plans to use the proceeds for working capital and general corporate purposes. The offering is expected to close on or about May 19, subject to customary conditions. A.G.P./Alliance Global Partners is acting as the sole placement agent. ## GOVX Stock: Critical Levels To Watch Even after the premarket drop, the stock is still trading 37.2% above its 20-day SMA ($1.33) and 30.6% above its 50-day SMA ($1.40), which tells you the intermediate bounce is still intact. The bigger picture remains heavy, though: shares are trading 15.1% below the 100-day SMA ($2.16) and 77.6% below the 200-day SMA ($8.16), keeping the long-term trend pointed down. Momentum is the key near-term tell, and RSI at 71.91 is in overbought territory—often a sign the move has gotten stretched and is vulnerable to profit-taking. The moving-average structure also shows why rallies have been hard to sustain: the 20-day SMA is still below the 50-day SMA, and the 50-day SMA is below the 200-day SMA—two bearish crossovers that usually describe a longer-term downtrend with counter-trend pops. **GOVX Price Action:** Geovax Labs shares were down 13.57% at $1.91 during premarket trading on Tuesday. The stock is trading near its 52-week low of $0.96, according to Benzinga Pro data. _Image via Shutterstock_ ### Related Stocks - [GOVX.US](https://longbridge.com/en/quote/GOVX.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [LABD.US](https://longbridge.com/en/quote/LABD.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md) - [GOVXW.US](https://longbridge.com/en/quote/GOVXW.US.md) ## Related News & Research - [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md) - [Rani Therapeutics Q1 contract revenue rises on Chugai collaboration; announces CFO transition](https://longbridge.com/en/news/286608288.md) - [GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats](https://longbridge.com/en/news/286807713.md) - [Dyadic International Q1 net loss narrows](https://longbridge.com/en/news/286311192.md) - [BUZZ-Street View: Regeneron's melanoma trial setback raises bigger-picture questions](https://longbridge.com/en/news/286769076.md)